Irinotecan hydrochloride is approved by the Food and Drug Administration (FDA) to be used with other drugs to treat colorectal cancer that has metastasized (spread to other parts of the body). It is also approved to treat metastatic colorectal cancer that has recurred (come back) or gotten worse after earlier chemotherapy. In addition to the uses that have been approved by the FDA, irinotecan hydrochloride is sometimes used to treat other types of cancer. Irinotecan hydrochloride is also being studied in the treatment of other types of cancer.
A new study indicates that the topoisomerase 1 (Top1) is intimately related to the lethal inflammation associated with SARS-CoV-2 infection in a large proportion of cases.
University of Houston professor of pharmaceutics Ming Hu is developing and testing an ancient Chinese herbal medicine formula, first described in 280 A.D., to improve cancer therapy.
Oncotarget recently published "Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer" which reported that the authors investigated whether Trop-2-expression and homologous recombination repair of SN-38-mediated double-strand DNA breaks play a role in the sensitivity of triple-negative breast cancer to SG.
A recent study published in the preprint server medRxiv in September 2020 shows that the already approved drug families called P13K/mTOR and topoisomerase inhibitors may be useful in reducing individual susceptibility to the virus.
Oncotarget Volume 11, Issue 34 features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et al which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib.
Now, a new study published on the preprint server bioRxiv in August 2020 reports the discovery of two inhibitors of the helicase enzyme, which is essential for viral replication and the most highly conserved non-structural coronavirus (CoV) protein.
Working with an international team of researchers, HonorHealth Research Institute and the Translational Genomics Research Institute, an affiliate of City of Hope, were instrumental in one of the first clinical trials showing how pancreatic cancer patients can benefit from immunotherapy, according to a four-year study published in a premier scientific journal, Nature Medicine.
Now, an intriguing new study out of the University of Wisconsin-Milwaukee reveals that numerous small molecule drugs like the proton pump inhibitors omeprazole and rabeprazole bind the important Mac1 domain on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus.
Researchers from SWOG, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, will make 31 presentations as part of the ASCO20 Virtual Scientific Program, the online annual meeting of the American Society of Clinical Oncology (ASCO), which runs May 29-31.
Researchers have found a way to help make chemotherapy more effective in treating colon cancer. They identified a new pathway (RICTOR/mTORC2) as a biological target for the disease.
A research team at Kobe University Hospital have further illuminated the likelihood of cancer drug side effects that can occur due to genetic mutations in the drug-metabolizing enzyme.
Final results are published from an evaluation of 42 patients treated with the immune checkpoint inhibitor nivolumab in the large multi-arm precision medicine trial, NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131).
Results presented today at the ESMO Congress 2019, Barcelona 27 September - 01 October, during the second Proffered Paper Session on Gastrointestinal tumors (colorectal) by VHIO's Director, Josep Tabernero, show that the triplet combination of the BRAF inhibitor, encorafenib, MEK inhibitor, binimetinib, and EGFR inhibitor, cetuximab, not only significantly improves overall survival but also increases objective response rates compared with standard of care in patients with BRAF V600E-mutant metastatic colorectal cancer.
A clinical trial has shown that using a combination of three drugs that target a BRAF gene mutation in patients with mCRC effectively boosts overall survival.
The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Advanced colon cancer often spreads widely and may not respond to standard chemotherapy. In such a case, a novel combination of drugs and flexible dosing may help achieve a better outlook, as demonstrated by several new studies.
Rhabdomyosarcoma is a rare cancer of the skeletal muscle that primarily affects pediatric patients. After diagnosis, about 3 out of 4 patients are cured with standard treatment. Survival rates drop to 17 percent if the disease comes back (recurs) and to 30 percent if it spreads (metastasizes).
A systematic review of research has revealed that the toxic effects on the lung of drugs commonly taken to treat a range of common conditions is much more widespread than thought.
Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy.